UA115133C2 - Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань - Google Patents

Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань

Info

Publication number
UA115133C2
UA115133C2 UAA201404855A UAA201404855A UA115133C2 UA 115133 C2 UA115133 C2 UA 115133C2 UA A201404855 A UAA201404855 A UA A201404855A UA A201404855 A UAA201404855 A UA A201404855A UA 115133 C2 UA115133 C2 UA 115133C2
Authority
UA
Ukraine
Prior art keywords
treatment
arylcarbonyl
oxy
neurodegenerative diseases
compounds useful
Prior art date
Application number
UAA201404855A
Other languages
English (en)
Inventor
Тацукі Коіке
Масато Йошікава
Харухі Андо
Уільям Джон Фарнебі
Original Assignee
Такеда Фармасьютікал Компані Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115133(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютікал Компані Лімітед filed Critical Такеда Фармасьютікал Компані Лімітед
Publication of UA115133C2 publication Critical patent/UA115133C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Даний винахід стосується сполуки, придатної як агент для профілактики або лікування нейродегенеративних захворювань тощо, або її солі. Даний винахід стосується сполуки, представленої формулою EMBED ISISServer , (I) де кожен символ є таким, як визначено у описі, або її солі.
UAA201404855A 2011-10-07 2012-10-03 Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань UA115133C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07
PCT/JP2012/076257 WO2013054822A1 (en) 2011-10-07 2012-10-03 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
UA115133C2 true UA115133C2 (uk) 2017-09-25

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201404855A UA115133C2 (uk) 2011-10-07 2012-10-03 Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань

Country Status (41)

Country Link
US (11) US9193709B2 (uk)
EP (1) EP2763979B1 (uk)
JP (1) JP6117191B2 (uk)
KR (1) KR101967497B1 (uk)
CN (1) CN103842356B (uk)
AP (1) AP2014007606A0 (uk)
AR (1) AR088226A1 (uk)
AU (1) AU2012321815B2 (uk)
BR (2) BR122022001219B1 (uk)
CA (1) CA2851087C (uk)
CL (1) CL2014000806A1 (uk)
CO (1) CO6940432A2 (uk)
CR (1) CR20140151A (uk)
CY (1) CY1121549T1 (uk)
DK (1) DK2763979T3 (uk)
DO (1) DOP2014000064A (uk)
EA (1) EA025662B1 (uk)
EC (1) ECSP14013329A (uk)
ES (1) ES2716531T3 (uk)
GE (1) GEP201706608B (uk)
HR (1) HRP20190491T1 (uk)
HU (1) HUE043171T2 (uk)
IL (1) IL231678A (uk)
LT (1) LT2763979T (uk)
MA (1) MA35623B1 (uk)
ME (1) ME03372B (uk)
MX (1) MX360706B (uk)
MY (1) MY176126A (uk)
PE (1) PE20141120A1 (uk)
PL (1) PL2763979T3 (uk)
PT (1) PT2763979T (uk)
RS (1) RS58470B1 (uk)
SG (1) SG2014010417A (uk)
SI (1) SI2763979T1 (uk)
TN (1) TN2014000122A1 (uk)
TR (1) TR201902788T4 (uk)
TW (1) TWI582084B (uk)
UA (1) UA115133C2 (uk)
UY (1) UY34365A (uk)
WO (1) WO2013054822A1 (uk)
ZA (1) ZA201402424B (uk)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2763979T (pt) 2011-10-07 2019-04-12 Takeda Pharmaceuticals Co Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas
WO2014061676A1 (ja) 2012-10-16 2014-04-24 武田薬品工業株式会社 複素環化合物
ES2695350T3 (es) 2012-12-11 2019-01-03 Takeda Pharmaceuticals Co Compuesto heterocíclico
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2982670B1 (en) 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015190613A1 (en) 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
HUE055199T2 (hu) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
EP3363796B1 (en) * 2015-10-16 2021-04-07 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017195894A1 (ja) * 2016-05-13 2017-11-16 日産化学工業株式会社 ２－アセチルピリジン化合物の製造方法
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CN111065394B (zh) * 2017-08-31 2023-03-31 武田药品工业株式会社 中枢神经系统病症的治疗
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3852757A1 (en) * 2018-09-20 2021-07-28 Takeda Pharmaceutical Company Limited Ch24h inhibitors for pain use
JP7189749B2 (ja) 2018-12-04 2022-12-14 株式会社日立産機システム スクリュー圧縮機
US20220332699A1 (en) * 2019-05-24 2022-10-20 Sage Therapeutics, Inc. Compounds, compositions, and methods of use
CA3203010A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
EP0929574B1 (en) 1996-08-27 2005-06-29 Praecis Pharmaceuticals Incorporated MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANIN CONCENTRATION HORMONE ANTAGONIST
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
WO2006137465A1 (ja) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ES2436616T5 (es) 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
WO2008134547A1 (en) * 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions
WO2008153722A1 (en) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MY150599A (en) 2008-08-22 2014-01-30 Sanofi Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
CN103201267B (zh) 2010-07-29 2016-08-17 里格尔药品股份有限公司 Ampk-激活性杂环化合物以及其使用方法
ES2650744T3 (es) 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
PT2763979T (pt) 2011-10-07 2019-04-12 Takeda Pharmaceuticals Co Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas

Also Published As

Publication number Publication date
CA2851087C (en) 2019-09-24
IL231678A0 (en) 2014-05-28
CR20140151A (es) 2014-05-26
US8865717B2 (en) 2014-10-21
JP2014528904A (ja) 2014-10-30
US10144743B2 (en) 2018-12-04
US9193709B2 (en) 2015-11-24
AU2012321815A8 (en) 2014-06-12
TN2014000122A1 (en) 2015-07-01
MA35623B1 (fr) 2014-11-01
CY1121549T1 (el) 2020-05-29
CO6940432A2 (es) 2014-05-09
ZA201402424B (en) 2015-07-29
US10717748B2 (en) 2020-07-21
US8648079B2 (en) 2014-02-11
US8871766B2 (en) 2014-10-28
DOP2014000064A (es) 2014-07-15
EA025662B1 (ru) 2017-01-30
ECSP14013329A (es) 2014-05-31
EP2763979A1 (en) 2014-08-13
GEP201706608B (en) 2017-01-25
US10273245B2 (en) 2019-04-30
AU2012321815A1 (en) 2014-04-24
HUE043171T2 (hu) 2019-08-28
US11174272B2 (en) 2021-11-16
KR101967497B1 (ko) 2019-04-09
US9440990B2 (en) 2016-09-13
TW201329068A (zh) 2013-07-16
BR112014007257A2 (pt) 2017-03-28
SI2763979T1 (sl) 2019-04-30
CN103842356A (zh) 2014-06-04
EP2763979B1 (en) 2018-12-26
CA2851087A1 (en) 2013-04-18
PL2763979T3 (pl) 2019-06-28
AU2012321815B2 (en) 2017-03-09
BR112014007257B1 (pt) 2023-04-25
US10550129B2 (en) 2020-02-04
MY176126A (en) 2020-07-24
MX360706B (es) 2018-11-14
US20140088146A1 (en) 2014-03-27
KR20140072902A (ko) 2014-06-13
PT2763979T (pt) 2019-04-12
US20140228373A1 (en) 2014-08-14
US20140088118A1 (en) 2014-03-27
EA201490747A1 (ru) 2014-08-29
RS58470B1 (sr) 2019-04-30
US20210206781A1 (en) 2021-07-08
ES2716531T3 (es) 2019-06-13
US20130090341A1 (en) 2013-04-11
CN103842356B (zh) 2017-03-15
JP6117191B2 (ja) 2017-04-19
BR122022001219B1 (pt) 2023-03-14
UY34365A (es) 2013-05-31
AR088226A1 (es) 2014-05-21
US20150376205A1 (en) 2015-12-31
DK2763979T3 (en) 2019-04-01
NZ623185A (en) 2016-01-29
TWI582084B (zh) 2017-05-11
US9586930B2 (en) 2017-03-07
ME03372B (me) 2020-01-20
US20200157117A1 (en) 2020-05-21
US20160326136A1 (en) 2016-11-10
SG2014010417A (en) 2014-06-27
HRP20190491T1 (hr) 2019-05-03
TR201902788T4 (tr) 2019-03-21
US20190233436A1 (en) 2019-08-01
CL2014000806A1 (es) 2014-09-05
PE20141120A1 (es) 2014-09-15
IL231678A (en) 2017-03-30
US20170145031A1 (en) 2017-05-25
US20190071455A1 (en) 2019-03-07
WO2013054822A1 (en) 2013-04-18
LT2763979T (lt) 2019-03-25
MX2014004253A (es) 2014-06-11
AP2014007606A0 (en) 2014-05-31

Similar Documents

Publication Publication Date Title
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
PH12015501316A1 (en) Heterocyclic compound
MY164776A (en) Heterocyclic compound
MX2013006113A (es) Compuestos biciclico.
MX343561B (es) Compuestos de imidazolpiridazina.
MD4659B1 (ro) Polimorf al inhibitorilor SYK
AU2012214029A8 (en) Rorgammat inhibitors
PH12016500225A1 (en) Novel quinoline-substituted compound
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX352928B (es) Compuestos de piridazina-amida.
MX342310B (es) Compuestos de tiazolopirimidina.
JO3387B1 (ar) مشتقات بيتولين
IN2014CN04558A (uk)
IN2014CN04449A (uk)
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
IN2014DN01629A (uk)
MX349548B (es) Compuestos de tienopirimidina.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
NZ707773A (en) Methods of treating liver diseases
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
PH12015502703A1 (en) Pharmaceutical compositions
TN2013000230A1 (en) Bicyclic compound
JO3723B1 (ar) مركبات دائرية مغايرة
TN2013000094A1 (en) Manufacturing process for pyrimidine derivatives